Last reviewed · How we verify
GSK233705
At a glance
| Generic name | GSK233705 |
|---|---|
| Also known as | salmeterol, tiotropium |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD (PHASE2)
- Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary Disease (PHASE2)
- Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects. (PHASE1)
- Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease (PHASE1)
- Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705 (PHASE1)
- A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers. (PHASE1)
- Phase I Study of GSK233705 in Healthy Japanese Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK233705 CI brief — competitive landscape report
- GSK233705 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI